title: The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience.
abstract: The treatment of persistent asthma has been aided by the recent approval of new medications. The combined inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) powder inhaler fluticasone furoate (FF)/vilanterol trifenatate (VI) is one of these new agents, which was recently approved as a maintenance therapy for persistent asthma. This once-daily ICS/LABA inhaler has previously been approved and used in chronic obstructive pulmonary disease as a maintenance therapy. Both FF and VI individually have been shown to have efficacy in the treatment of persistent asthma; the combination of FF/VI at the dose of 100/25 μg daily improves trough peak expiratory flows and forced expiratory volume in 1 s. It also reduces the frequency of asthma exacerbations in patients with persistent asthma. The once-daily dosing is well tolerated, with limited clinically significant adverse events; the once-daily inhaled dosing regimen should also improve medication adherence. The data supporting the use of the FF/VI inhaler in persistent asthma are reviewed. The dry powder inhaler of FF/VI (100/25 μg) is an effective and well tolerated once-daily maintenance treatment for patients with persistent asthma.
authors.affiliation: Division of Pulmonary, Critical Care Medicine, Department of Internal Medicine and VA Northern California Healthcare Center, Mather UC Davis School of Medicine, 4150 V Street, Suite 3100, Sacramento, CA 95817, USA tealbertson@ucdavis.edu.
authors.forename: Timothy E
authors.initials: TE
authors.lastname: Albertson
authors.affiliation: Department Emergency Medicine, University of California, Davis, Sacramento, CA, USA.
authors.forename: John R
authors.initials: JR
authors.lastname: Richards
authors.affiliation: Division of Pulmonary, Critical Care and Sleep Medicine University of California, Davis, Sacramento, CA, USA.
authors.forename: Amir A
authors.initials: AA
authors.lastname: Zeki
mesh_terms: D000280:Administration, Inhalation; D000730:Androstadienes / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001592:Benzyl Alcohols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002722:Chlorobenzenes / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004338:Drug Combinations; D005541:Forced Expiratory Volume; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans
chemical_list: D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D001592:Benzyl Alcohols; D002722:Chlorobenzenes; D004338:Drug Combinations; D005938:Glucocorticoids; C550468:vilanterol; C523187:fluticasone furoate
keywords: combined inhaler; fluticasone furoate/vilanterol trifenatate; inhaled corticosteroid; long-acting β2 agonist; persistent asthma; powder inhaler